AOD9604 Peptide 6mg

Peptide Science research editorial team.

AOD-9604 Peptide 6mg Overview

AOD-9604 Peptide 6mg from Peptide Science is the 16-amino-acid C-terminal fragment of human growth hormone (hGH residues 177 to 191), supplied as a lyophilised vial for in-vitro lipolytic-pathway and preclinical adipose-tissue research. The molecule is sometimes designated “anti-obesity drug 9604” in the literature, reflecting its original characterisation as the lipolytic domain of the parent 191-residue hGH protein with the somatotropic activity removed by truncation.

Mechanism in Adipose Research

AOD-9604 corresponds to hGH residues 177 to 191 with an additional N-terminal tyrosine for stability, giving a 16-amino-acid peptide. Preclinical research has characterised the fragment for lipolytic activity in cultured adipocytes via beta-3 adrenergic-receptor-adjacent pathways, without measurable IGF-1 or GH-axis signalling because the full hGH receptor-binding domain is absent. The compound is studied as a research tool for separating the lipolytic from the somatotropic actions of the parent hGH protein. Browse the broader metabolic peptide research range for context.

Specifications

Reconstitution and Handling

The lyophilised fragment reconstitutes with bacteriostatic water for cell-culture or animal-model work. For paired research with the NNMT-pathway compound, see 5-Amino-1MQ 50mg 60-Capsule.

Quality and Shipping

Each batch passes HPLC at greater than 99 percent purity, with mass-spectrometry confirmation against the 1817 g/mol theoretical molecular weight. A Certificate of Analysis accompanies every order. Material is filled in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in insulated, temperature-monitored packaging via overnight or two-day courier.

For laboratory research and development use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease, including obesity or type 2 diabetes. Has not been evaluated by the U.S. Food and Drug Administration. Branded therapeutic GLP-1, GIP, and dual-agonist medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription-only medicines in the United States and are not the same as research-grade compounds supplied for in-vitro work. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws.